Literature DB >> 31111305

Application of Mechanistic Ocular Absorption Modeling and Simulation to Understand the Impact of Formulation Properties on Ophthalmic Bioavailability in Rabbits: a Case Study Using Dexamethasone Suspension.

Maxime Le Merdy1, Jianghong Fan2, Michael B Bolger3, Viera Lukacova3, Jessica Spires3, Eleftheria Tsakalozou1, Vikram Patel4, Lin Xu4, Sharron Stewart4, Ashok Chockalingam4, Suresh Narayanasamy4, Rodney Rouse4, Murali Matta4, Andrew Babiskin1, Darby Kozak5, Stephanie Choi6, Lei Zhang6, Robert Lionberger6, Liang Zhao1.   

Abstract

Developing mathematical models to predict changes in ocular bioavailability and pharmacokinetics due to differences in the physicochemical properties of complex topical ophthalmic suspension formulations is important in drug product development and regulatory assessment. Herein, we used published FDA clinical pharmacology review data, in-house, and literature rabbit pharmacokinetic data generated for dexamethasone ophthalmic suspensions to demonstrate how the mechanistic Ocular Compartmental Absorption and Transit model by GastroPlus™ can be used to characterize ocular drug pharmacokinetic performance in rabbits for suspension formulations. This model was used to describe the dose-dependent (0.01 to 0.1%) non-linear pharmacokinetic in ocular tissues and characterize the impact of viscosity (1.67 to 72.9 cP) and particle size (5.5 to 22 μm) on in vivo ocular drug absorption and disposition. Parameter sensitivity analysis (hypothetical suspension particle size: 1 to 10 μm, viscosity: 1 to 100 cP) demonstrated that the interplay between formulation properties and physiological clearance through drainage and tear turnover rates in the pre-corneal compartment drives the ocular drug bioavailability. The quick removal of drug suspended particles from the pre-corneal compartment renders the impact of particle size inconsequential relative to viscosity modification. The in vivo ocular absorption is (1) viscosity non-sensitive when the viscosity is high and the impact of viscosity on the pre-corneal residence time reaches the maximum physiological system capacity or (2) viscosity sensitive when the viscosity is below a certain limit. This study reinforces our understanding of the interplay between physiological factors and ophthalmic formulation physicochemical properties and their impact on in vivo ocular drug PK performance in rabbits.

Entities:  

Keywords:  bioequivalence; dexamethasone; ocular PBPK; particle size; simulation; viscosity

Year:  2019        PMID: 31111305     DOI: 10.1208/s12248-019-0334-x

Source DB:  PubMed          Journal:  AAPS J        ISSN: 1550-7416            Impact factor:   4.009


  25 in total

1.  Prediction of human clearance of twenty-nine drugs from hepatic microsomal intrinsic clearance data: An examination of in vitro half-life approach and nonspecific binding to microsomes.

Authors:  R S Obach
Journal:  Drug Metab Dispos       Date:  1999-11       Impact factor: 3.922

Review 2.  Permeability of cornea, sclera, and conjunctiva: a literature analysis for drug delivery to the eye.

Authors:  M R Prausnitz; J S Noonan
Journal:  J Pharm Sci       Date:  1998-12       Impact factor: 3.534

3.  Mechanistic studies on transcorneal permeation of pilocarpine.

Authors:  J W Sieg; J R Robinson
Journal:  J Pharm Sci       Date:  1976-12       Impact factor: 3.534

4.  Ocular evaluation of polyvinyl alcohol vehicle in rabbits.

Authors:  T F Patton; J R Robinson
Journal:  J Pharm Sci       Date:  1975-08       Impact factor: 3.534

5.  Solubilization of hydrocortisone, dexamethasone, testosterone and progesterone by long-chain polyoxyethylene surfactants.

Authors:  B W Barry; D I El Eini
Journal:  J Pharm Pharmacol       Date:  1976-03       Impact factor: 3.765

6.  Pharmacokinetics of topically applied pilocarpine in the albino rabbit eye.

Authors:  M C Makoid; J R Robinson
Journal:  J Pharm Sci       Date:  1979-04       Impact factor: 3.534

Review 7.  Implications of melanin binding in ocular drug delivery.

Authors:  Anna-Kaisa Rimpelä; Mika Reinisalo; Laura Hellinen; Evgeni Grazhdankin; Heidi Kidron; Arto Urtti; Eva M Del Amo
Journal:  Adv Drug Deliv Rev       Date:  2017-12-13       Impact factor: 15.470

8.  Preliminary pharmacokinetic model of pilocarpine uptake and distribution in the eye.

Authors:  K J Himmelstein; I Guvenir; T F Patton
Journal:  J Pharm Sci       Date:  1978-05       Impact factor: 3.534

9.  Pharmacokinetic study of dexamethasone disodium phosphate using intravitreal, subconjunctival, and intravenous delivery routes in rabbits.

Authors:  Kamran Hosseini; Dani Matsushima; Juanita Johnson; Georg Widera; Kofi Nyam; Lomi Kim; Yaodong Xu; Yongjin Yao; Michel Cormier
Journal:  J Ocul Pharmacol Ther       Date:  2008-06       Impact factor: 2.671

10.  Impact of Vehicle Physicochemical Properties on Modeling-Based Predictions of Cyclosporine Ophthalmic Emulsion Bioavailability and Tear Film Breakup Time.

Authors:  Ross L Walenga; Andrew H Babiskin; Xinyuan Zhang; Mohammad Absar; Liang Zhao; Robert A Lionberger
Journal:  J Pharm Sci       Date:  2018-10-29       Impact factor: 3.534

View more
  6 in total

1.  Clinical Ocular Exposure Extrapolation for Ophthalmic Solutions Using PBPK Modeling and Simulation.

Authors:  Maxime Le Merdy; Farah AlQaraghuli; Ming-Liang Tan; Ross Walenga; Andrew Babiskin; Liang Zhao; Viera Lukacova
Journal:  Pharm Res       Date:  2022-09-23       Impact factor: 4.580

2.  Physiologically Based Pharmacokinetic Model to Support Ophthalmic Suspension Product Development.

Authors:  Maxime Le Merdy; Ming-Liang Tan; Andrew Babiskin; Liang Zhao
Journal:  AAPS J       Date:  2020-01-06       Impact factor: 4.009

Review 3.  Physiologically-based pharmacokinetic modeling to support bioequivalence and approval of generic products: A case for diclofenac sodium topical gel, 1.

Authors:  Eleftheria Tsakalozou; Andrew Babiskin; Liang Zhao
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2021-03-09

4.  Biopharmaceutics of Topical Ophthalmic Suspensions: Importance of Viscosity and Particle Size in Ocular Absorption of Indomethacin.

Authors:  Elisa Toropainen; Sara J Fraser-Miller; Dunja Novakovic; Eva M Del Amo; Kati-Sisko Vellonen; Marika Ruponen; Tapani Viitala; Ossi Korhonen; Seppo Auriola; Laura Hellinen; Mika Reinisalo; Unni Tengvall; Stephanie Choi; Mohammad Absar; Clare Strachan; Arto Urtti
Journal:  Pharmaceutics       Date:  2021-03-26       Impact factor: 6.321

5.  Ocular Physiologically Based Pharmacokinetic Modeling for Ointment Formulations.

Authors:  Maxime Le Merdy; Jessica Spires; Viera Lukacova; Ming-Liang Tan; Andrew Babiskin; Xiaoming Xu; Liang Zhao; Michael B Bolger
Journal:  Pharm Res       Date:  2020-11-19       Impact factor: 4.200

6.  Development of PBPK model for intra-articular injection in human: methotrexate solution and rheumatoid arthritis case study.

Authors:  Maxime Le Merdy; Jim Mullin; Viera Lukacova
Journal:  J Pharmacokinet Pharmacodyn       Date:  2021-09-26       Impact factor: 2.745

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.